Ciprofol's Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients

Launched by FIRST AFFILIATED HOSPITAL OF WANNAN MEDICAL COLLEGE · Apr 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new sedative called Ciprofol to see how it affects patients who are on Extracorporeal Membrane Oxygenation (ECMO), a life-support system used for people with severe heart or lung problems. The main goal is to understand if Ciprofol is safer and more effective than a commonly used sedative, midazolam, especially in terms of how it impacts the oxygenator, a key part of the ECMO machine that helps add oxygen to the blood. Eligible participants are adults aged 18 and older who have been on ECMO for more than 72 hours and require sedation for medical procedures.

If someone joins the study, they will be randomly placed in one of two groups: one will receive Ciprofol and the other midazolam, with the doses adjusted as needed to keep them safe and comfortable. The researchers will monitor how well the oxygenator works and look for any side effects over the first week. This trial is important because it could lead to better sedation practices for critically ill patients, potentially improving their recovery and the performance of the ECMO device.

Gender

ALL

Eligibility criteria

• 1. Inclusion Criteria:
• • Receiving ECMO therapy with an anticipated duration exceeding 72 hours;
• • Requiring invasive mechanical ventilation;
• • Requiring sedation and analgesia treatment.
• 2. Exclusion Criteria:
• • BMI \>45 kg/m²;
• • Age \<18 years;
• • Severe hepatic (Child-Pugh Class C) or renal failure (eGFR \<15 mL/min/1.73m²);
• • History of severe psychiatric disorders;
• • Pregnancy;
• • Refusal to sign informed consent;
• • Contraindications to midazolam and propofol use.